Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 2 September 2024, 14:12 HKT/SGT
Share:
    

Source: Eisai
Eisai Announces Status Relating to Acquisition of Own Shares

Eisai Co., Ltd. announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act. The status (progress report) of the acquisition is as described below.

1. Class of shares acquired: Ordinary shares of the Company
2. Total number of shares acquired: 1,598,800 shares
3. Aggregate amount of acquisition cost: JPY9,100,754,577
4. Acquisition period: From August 1 to August 31, 2024 (execution basis)
5. Acquisition method: Open market purchase through the Tokyo Stock Exchange based on a discretionary trading contract

For Reference

1. Resolution at a meeting of the Board of Directors held on May 15, 2024

(1) Class of shares to be acquired: Ordinary shares of the Company
(2) Total number of shares to be acquired: 6,500,000 shares (maximum)
(Ratio to total number of issued shares (excluding treasury shares): 2.3%)
(3) Total amount of acquisition cost: JPY30.0 billion (maximum)
(4) Period of acquisition: From May 16, 2024 to November 15, 2024
(5) Acquisition method: Open market purchase through the Tokyo Stock Exchange based on a discretionary trading contract

2. Accumulated number and price of own shares acquired in accordance with the above mentioned resolution at the meeting of Board of Directors (as of August 31, 2024)
(1) Total number of shares acquired: 4,037,300 shares
(2) Aggregate amount of acquisition cost: JPY24,933,137,242




Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Feb 16, 2026 13:03 HKT/SGT
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
Feb 10, 2026 12:34 HKT/SGT
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Feb 6, 2026 10:31 HKT/SGT
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
Jan 26, 2026 10:37 HKT/SGT
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Jan 21, 2026 15:44 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
Jan 13, 2026 08:50 HKT/SGT
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Jan 6, 2026 09:43 HKT/SGT
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
Dec 11, 2025 18:41 HKT/SGT
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
Dec 9, 2025 17:51 HKT/SGT
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
Dec 4, 2025 17:36 HKT/SGT
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
More news >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: